APP and early-onset autosomal dominant Alzheimer disease: In Alzheimer’s disease, CRISPR-Cas9 reduces β-amyloid deposition by knocking out APP and PSEN1 genes, alleviating neuroinflammation and improving cognitive function (Yoon et al., 2024).